日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

普拉替尼治疗晚期RET融合阳性非小细胞肺癌患者的I/II期ARROW研究的最终疗效和安全性数据

Besse, Benjamin; Subbiah, Vivek; Curigliano, Giuseppe; Bowles, Daniel W; Doebele, Robert C; Mansfield, Aaron S; Baik, Christina S; de Lima Lopes, Gilberto; Paz-Ares, Luis; Taylor, Matthew H; Tan, Daniel S W; Alonso, Guzman; Gadgeel, Shirish M; Kalemkerian, Gregory P; Ou, Sai-Hong Ignatius; van der Wekken, Anthonie J; Becerra, Carlos R; Evangelist, Makenzi; Griesinger, Frank; Liu, Stephen V; Lou, Yanyan; Mazières, Julien; Melear, Jason M; Narang, Mohit; Saxena, Ashish; Thomas, Michael; Wang, Sophia; Thomassen, Amber; Lee, Dae Ho; Kim, Dong-Wan; Gainor, Justin F

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

Ifinatamab Deruxtecan治疗广泛期小细胞肺癌患者:II期IDeate-Lung01试验的主要分析

Rudin, Charles M; Johnson, Melissa L; Paz-Ares, Luis; Nishio, Makoto; Hann, Christine L; Girard, Nicolas; Rocha, Pedro; Hayashi, Hidetoshi; Sakai, Tetsuya; Kim, Yu Jung; Hu, Haichuan; Qian, Meng; Singh, Jasmeet; Godard, Juliette; Tang, Mei; Ahn, Myung-Ju

NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum.

MDM2 对 NOTCH1 胞内结构域的稳定作用在非小细胞肺癌对铂类药物的反应中起着重要作用。

Bernardo Sara, Brunet Lisa, Thomas Quentin Dominique, Bracquemond David, Bouclier Céline, Colomb Marie, Mancini Maicol, Fabbrizio Eric, Santos Alba, Rasamizafy Sylvia-Fenosoa, Maacha Amina-Milissa, Giry Anais, Bousquet-Mur Emilie, Papon Laura, Goussard Marion, Fremin Christophe, Pasquier Andrea, Rodríguez María, Travert Camille, Pujol Jean-Louis, Linares Laetitia K, Heron-Milhavet Lisa, Djiane Alexandre, Ferrer Irene, Paz-Ares Luis, Quantin Xavier, Montuenga Luis M, Tourriere Hélène, Maraver Antonio

Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)

循环免疫细胞上基线 PD-L1 表达作为接受度伐利尤单抗和卡铂-依托泊苷治疗的广泛期小细胞肺癌患者生存期和免疫相关不良事件的预测因子(NCT04712903 试验)

Piedra, Aida; Guinart-Cuadra, Albert; Martínez-Recio, Sergio; Mulet, Maria; Zamora, Carlos; Osuna-Gómez, Rubén; Cantó, Elisabet; Ortiz, Maria Angels; Alejandre, José; Barba, Andrés; Sanz-Beltrán, Judit; Serra-López, Jorgina; Isla, Dolores; Arriola, Edurne; Paz-Ares, Luis; Diz-Taín, María Pilar; Moreno, Alberto Luis; Callejo, Ángel; Vidal, Silvia; Majem, Margarita

Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial

Sacituzumab Govitecan 与多西他赛治疗转移性非小细胞肺癌的患者报告症状和生活质量:3 期随机 EVOKE-01 试验

Reinmuth, Niels; Couraud, Sébastien; Paz-Ares, Luis; Garassino, Marina Chiara; Baijal, Shobhit; Daniel, Davey; Garrido, Pilar; Kato, Terufumi; Percent, Ivor; Rittmeyer, Achim; Parra, Hector Soto; Mekan, Sabeen; Patel, Mira; Radford, Matthew; Zhang, Eric; Pelligra, Christopher G; Guo, Shien; Felip, Enriqueta

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Divarasib 单药治疗 KRAS G12C 阳性非小细胞肺癌患者:一项 I 期研究的长期随访

Sacher, Adrian G; Miller, Wilson H Jr; Patel, Manish R; Paz-Ares, Luis; Santoro, Armando; Ahn, Myung-Ju; Dziadziuszko, Rafal; Freres, Pierre; Luo, Jia; Bowyer, Samantha; Desai, Jayesh; Markman, Ben; De Miguel, Maria; Deva, Sanjeev; Falcon, Alejandro; Alonso, Guzman; Guedes, João Daniel; Kim, Se Hyun; Krebs, Matthew G; Laurie, Scott A; Massarelli, Erminia; Medina, Laura; Prenen, Hans; Amatu, Alessio; Van Dongen, Marloes; Choi, Yoonha; Hou, Xuefeng; Qi, Ting; Lin, Mark T; Koli, Kalpesh; Mayo, Mariah C; Yau, Kenneth K; Royer-Joo, Stephanie; Chang, Julie; Jun, Tomi; Dharia, Neekesh V; Schutzman, Jennifer L; Lorusso, Patricia

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

达托泊单抗德鲁替康对比多西他赛治疗既往接受过治疗的晚期或转移性非小细胞肺癌:随机、开放标签的 III 期 TROPION-Lung01 研究

Ahn, Myung-Ju; Tanaka, Kentaro; Paz-Ares, Luis; Cornelissen, Robin; Girard, Nicolas; Pons-Tostivint, Elvire; Vicente Baz, David; Sugawara, Shunichi; Cobo, Manuel; Pérol, Maurice; Mascaux, Céline; Poddubskaya, Elena; Kitazono, Satoru; Hayashi, Hidetoshi; Hong, Min Hee; Felip, Enriqueta; Hall, Richard; Juan-Vidal, Oscar; Brungs, Daniel; Lu, Shun; Garassino, Marina; Chargualaf, Michael; Zhang, Yong; Howarth, Paul; Uema, Deise; Lisberg, Aaron; Sands, Jacob

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

达托泊单抗德鲁西替康治疗具有可靶向基因组改变的晚期或转移性非小细胞肺癌:来自 II 期 TROPION-Lung05 研究的结果

Sands, Jacob; Ahn, Myung-Ju; Lisberg, Aaron; Cho, Byoung Chul; Blumenschein, George Jr; Shum, Elaine; Pons Tostivint, Elvire; Goto, Yasushi; Yoh, Kiyotaka; Heist, Rebecca; Shimizu, Junichi; Lee, Jong-Seok; Baas, Paul; Planchard, David; Pérol, Maurice; Felip, Enriqueta; Su, Wu-Chou; Zebger-Gong, Hong; Lan, Lan; Liu, Chelsea; Howarth, Paul; Chiaverelli, Rachel; Paz-Ares, Luis

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.

高保真 Cas9 介导的 KRAS 驱动突变靶向治疗可在临床前模型中抑制肺癌

Álvarez-Pérez Juan Carlos, Sanjuán-Hidalgo Juan, Arenas Alberto M, Hernández-Navas Ivan, Benitez-Cantos Maria S, Andrades Alvaro, Calabuig-Fariñas Silvia, Jantus-Lewintre Eloisa, Paz-Ares Luis, Ferrer Irene, Medina Pedro P

Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data

基于真实世界数据,监测外周血数据有助于预测晚期非小细胞肺癌的免疫治疗反应。

Ramos-Guerra, Ana D; Farina, Benito; Rubio Pérez, Jaime; Vilalta-Lacarra, Anna; Zugazagoitia, Jon; Peces-Barba, Germán; Seijo, Luis M; Paz-Ares, Luis; Gil-Bazo, Ignacio; Dómine Gómez, Manuel; Ledesma-Carbayo, María J